{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:36:41Z","timestamp":1793824601665,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ijantimicag.2018.06.001","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T20:28:04Z","timestamp":1528835284000},"page":"258-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-5748","authenticated-orcid":false,"given":"Isabel","family":"Rodriguez-Goncer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kosmidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eavan G.","family":"Muldoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pippa J.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-2251","authenticated-orcid":false,"given":"David W.","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0001","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1086\/376526","article-title":"Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: Case series, proposed nomenclature change, and review","volume":"37","author":"Denning","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0002","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1378\/chest.14-0917","article-title":"Diagnosis and treatment of pulmonary aspergillosis syndromes","volume":"146","author":"Patterson","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0003","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1007\/s00330-015-3690-7","article-title":"Chronic aspergillosis of the lungs: Unravelling the terminology and radiology","volume":"25","author":"Desai","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0004","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2471\/BLT.11.089441","article-title":"Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis","volume":"89","author":"Denning","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: Human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0006","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2169\/internalmedicine.52.9142","article-title":"Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis","volume":"52","author":"Nakamoto","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0007","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1126\/science.aaa6097","article-title":"How to bolster the antifungal pipeline","volume":"347","author":"Denning","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01062-2016","article-title":"Predictors of mortality in chronic pulmonary aspergillosis","volume":"49","author":"Lowes","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/myc.12075","article-title":"Itraconazole in chronic cavitary pulmonary aspergillosis: A randomised controlled trial and systematic review of literature","volume":"56","author":"Agarwal","year":"2013","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/cid\/cir179","article-title":"High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease","volume":"52","author":"Denning","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amjmed.2005.11.028","article-title":"Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis","volume":"119","author":"Sambatakou","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0012","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1378\/chest.06-2441","article-title":"Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients","volume":"131","author":"Camuset","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0013","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s10096-012-1690-y","article-title":"Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial","volume":"31","author":"Cadranel","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0014","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s15010-012-0322-x","article-title":"Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: Experience in Japan","volume":"40","author":"Saito","year":"2012","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: Rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0016","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0017","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/657306","article-title":"Efficacy and safety of posaconazole for chronic pulmonary aspergillosis","volume":"51","author":"Felton","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0018","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1378\/chest.12-0014","article-title":"Validity and reliability of the St. George's respiratory questionnaire in assessing health status in patients with chronic pulmonary aspergillosis","volume":"144","author":"Al-Shair","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0019","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive","volume":"46","author":"Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0020","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/cid\/cit411","article-title":"Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: A longitudinal analysis","volume":"57","author":"Al-Shair","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0021","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.02.00063702","article-title":"Interpreting thresholds for a clinically significant change in health status in asthma and COPD","volume":"19","author":"Jones","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0022","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.03.020","article-title":"Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA)","volume":"114","author":"Al-Shair","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0023","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1469-0691.2011.03732.x","article-title":"HPLC\/UV or bioassay: Two valid methods for posaconazole quantification in human serum samples","volume":"18","author":"Cendejas-Bueno","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0024","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1128\/AAC.00901-08","article-title":"International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations","volume":"53","author":"Br\u00fcggemann","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0025","doi-asserted-by":"crossref","first-page":"E241","DOI":"10.1111\/j.1469-0691.2012.03854.x","article-title":"Isothermal microcalorimetry: A novel method for real-time determination of antifungal susceptibility of Aspergillus species","volume":"18","author":"Furustrand Tafin","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0026","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.00156-08","article-title":"Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus","volume":"52","author":"Rodriguez-Tudela","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0027","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drup.2009.09.002","article-title":"Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints","volume":"12","author":"Verweij","year":"2009","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0028","doi-asserted-by":"crossref","DOI":"10.1111\/j.1469-0691.2012.03890.x","article-title":"EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole","volume":"18","author":"Arendrup","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0029","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.ijid.2009.07.011","article-title":"Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases","volume":"14","author":"Nam","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0030","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0031","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jinf.2016.06.001","article-title":"Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis","volume":"73","author":"Newton","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0032","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/fmb.11.158","article-title":"A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy","volume":"7","author":"Huang","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0033","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/504328","article-title":"Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0034","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: A broad-spectrum triazole antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.06.001_bib0035","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918301584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918301584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T10:45:05Z","timestamp":1561718705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918301584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0924857918301584"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.06.001","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}